Focal Therapy for Localized Prostate Cancer: A Phase I/II Trial
- 30 April 2011
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 185 (4), 1246-1255
- https://doi.org/10.1016/j.juro.2010.11.079
Abstract
Men with localized prostate cancer currently face a number of treatment options that treat the entire prostate. These can cause significant sexual and urinary side effects. Focal therapy offers a novel strategy that targets the cancer rather than the prostate in an attempt to preserve tissue and function. A prospective, ethics committee approved trial was conducted to determine the side effects of focal therapy using high intensity focused ultrasound. Multiparametric magnetic resonance imaging (T2-weighted, dynamic contrast enhanced, diffusion-weighted) and template transperineal prostate mapping biopsies were used to identify unilateral disease. Genitourinary side effects and quality of life outcomes were assessed using validated questionnaires. Posttreatment biopsies were performed at 6 months and followup was completed to 12 months. A total of 20 men underwent high intensity focused ultrasound hemiablation. Mean age was 60.4 years (SD 5.4, range 50 to 70) with mean prostate specific antigen 7.3 ng/ml (SD 2.8, range 3.4 to 11.8). Of the men 25% had low risk and 75% had intermediate risk cancer. Return of erections sufficient for penetrative sex occurred in 95% of men (19 of 20). In addition, 90% of men (18 of 20) were pad-free, leak-free continent while 95% were pad-free. Mean prostate specific antigen decreased 80% to 1.5 ng/ml (SD 1.3) at 12 months. Of the men 89% (17 of 19, 1 refused biopsy) had no histological evidence of any cancer, and none had histological evidence of high volume or Gleason 7 or greater cancer in the treated lobe. In addition, 89% of men achieved the trifecta status of pad-free, leak-free continence, erections sufficient for intercourse and cancer control at 12 months. Our results appear sufficiently promising to support the further evaluation of focal therapy as a strategy to decrease some of the harms and costs associated with standard whole gland treatments.Keywords
This publication has 28 references indexed in Scilit:
- Tumor Volume in Radical Prostatectomy Specimens Assessed by Digital Image Analysis Software Correlates With Other Prognostic FactorsJournal of Urology, 2010
- Risk Stratification of Men Choosing Surveillance for Low Risk Prostate CancerJournal of Urology, 2010
- Tumor Percent Involvement Predicts Prostate Specific Antigen Recurrence After Radical Prostatectomy Only in Men With Smaller ProstateJournal of Urology, 2010
- Time Trends and Local Variation in Primary Treatment of Localized Prostate CancerJournal of Clinical Oncology, 2010
- Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate CancerJournal of Clinical Oncology, 2010
- Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate CancerAnnals of Internal Medicine, 2008
- Focal Therapy for Localized Prostate Cancer: A Critical Appraisal of Rationale and ModalitiesJournal of Urology, 2007
- Group Consensus Reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006Urology, 2007
- Will focal therapy become a standard of care for men with localized prostate cancer?Nature Clinical Practice Oncology, 2007
- THE PROSTATE SPECIFIC ANTIGEN ERA IN THE UNITED STATES IS OVER FOR PROSTATE CANCER: WHAT HAPPENED IN THE LAST 20 YEARS?Journal of Urology, 2004